Your session is about to expire
← Back to Search
VIC-1911 for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new drug to treat KRAS G12C-mutant NSCLC. The drug will be given alone and in combination with another drug to see how well it works.
- Non-Small Cell Lung Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have noticeable symptoms of cancer spreading to your brain or spinal cord.You have digestive problems that could make it difficult for your body to properly absorb or tolerate the study drugs.You have had a serious infection that required intravenous antibiotics within the past week before starting the study treatment.You have been treated with drugs that target MEK or EGFR in the past.You are allergic to VIC-1911 or any of its ingredients.You are unable to swallow pills or other oral medications.You have a lung condition that is causing symptoms and needs medical treatment.You have participated in or dropped out of a study testing a drug that inhibits aurora kinase A in the past.You cannot take any medications that affect UDP-glucuronosyltransferases (UGTs) during the initial phase of the study.You have had eye problems in the past that caused blurry vision or if a recent eye exam shows any important issues.
- Group 1: Dose Escalation Phase, Cohort 1a: VIC-1911 monotherapy
- Group 2: Dose Escalation Phase, Cohort 1b: VIC-1911 plus sotorasib combination therapy
- Group 3: Expansion Phase, Cohort 2c: VIC-1911 plus sotorasib combination therapy
- Group 4: Expansion Phase, Cohort 2a: VIC-1911 monotherapy
- Group 5: Expansion Phase, Cohort 2b: VIC-1911 plus sotorasib combination therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment currently available for this medical experiment?
"According to information on clinicaltrials.gov, this medical trial is no longer open for recruitment after being initially published on September 1st 2022 and last modified August 12th 2022. However, there are presently 1950 other studies that prospective patients can take part in."
Is VIC-1911 a secure medication for patients to use?
"Due to the limited amount of clinical data available, our team at Power gave VIC-1911 a score of 1 on the safety scale. This is because it's still in its first phase of testing and has yet to be proven safe or effective."
How many medical centers are engaged in overseeing this clinical trial?
"Potential enrollees in this trial have access to University of Maryland Cancer Center (Baltimore), Yale Cancer Center (North Haven) and NYULangone Health PerlmutterCancerCenter(New york). Additionally, there are five other sites available."
Share this study with friends
Copy Link
Messenger